Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing - Wikidata - wikimedia - TriplyDB

Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing

Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing

http://www.wikidata.org/entity/Q24632749

about

Cancer pharmacogenomics: strategies and challenges Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process.Acute lymphoblastic leukaemia CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network Impact of New Genomic Technologies on Understanding Adverse Drug Reactions Role of Pharmacogenetics in Hematopoietic Stem Cell Transplantation Outcome in Children Use of thiopurines in inflammatory bowel disease Therapeutic drug monitoring in inflammatory bowel disease Thiopurine monitoring in children with inflammatory bowel disease: a systematic review Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?Pharmacogenetics and anaesthesia: the value of genetic profiling Using germline genomics to individualize pediatric cancer treatments Germline pharmacogenomics in oncology: decoding the patient for targeting therapy Pharmacogenomics of chemotherapeutic susceptibility and toxicity Pitfalls of haplotype phasing from amplicon-based long-read sequencing Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use Economic Evaluation of Pharmacogenetic Tests in Patients Subjected to Renal Transplantation: A Review of Literature Advantages of Array-Based Technologies for Pre-Emptive Pharmacogenomics Testing Species differences in tumour responses to cancer chemotherapy Pharmacogenomics: personalizing pediatric heart transplantation Optimizing the use of thiopurines in inflammatory bowel disease Personalization of the immunosuppressive treatment in renal transplant recipients: the great challenge in "omics" medicine Progress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicity Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy Pharmacogenomics and personalized medicine: a review focused on their application in the Chinese population NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity Phenome-wide association studies on a quantitative trait: application to TPMT enzyme activity and thiopurine therapy in pharmacogenomics Enhanced specificity of TPMT*2 genotyping using unidirectional wild-type and mutant allele-specific scorpion primers in a single tube Association between thiopurine S-methyltransferase polymorphisms and thiopurine-induced adverse drug reactions in patients with inflammatory bowel disease: a meta-analysis Association between Thiopurine S-Methyltransferase Polymorphisms and Azathioprine-Induced Adverse Drug Reactions in Patients with Autoimmune Diseases: A Meta-Analysis Crowdsourced direct-to-consumer genomic analysis of a family quartet Assessment of Thiopurine-based drugs according to Thiopurine S-methyltransferase genotype in patients with Acute Lymphoblastic Leukemia Genes implicated in thiopurine-induced toxicity: Comparing TPMT enzyme activity with clinical phenotype and exome data in a paediatric IBD cohort.Prevalence of TPMT and ITPA gene polymorphisms and effect on mercaptopurine dosage in Chilean children with acute lymphoblastic leukemia.Host thiopurine methyltransferase status affects mercaptopurine antileukemic effectiveness in a murine model The Promise of Pharmacogenomics in Reducing Toxicity During Acute Lymphoblastic Leukemia Maintenance Treatment.Current approaches to the management of new-onset ulcerative colitis.Imputation of TPMT defective alleles for the identification of patients with high-risk phenotypes Thiopurine pharmacogenomics: association of SNPs with clinical response and functional validation of candidate genes.Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk.

P2860

Q24289309-39FC659C-C9AF-460D-9476-A8F4B9516574 Q24567778-78F9925D-08CB-4D0D-BFD4-53CEBF6F0B29 Q24602387-D287853D-6E3F-4C25-8934-9282B072F216 Q24632735-577AA5FA-D725-45A2-8654-F6D698AE03A6 Q26787099-6992B4FE-295B-47EA-986D-8D4ED1466917 Q26798470-8A43F667-83D9-42D2-A344-5F22246B1E16 Q26824662-E60C0138-797B-4701-B388-3B65BEBF2A71 Q26852729-9E3BEE22-0BB3-467B-8BFE-632DC00E017F Q26859122-29679425-AF27-4F1E-8ABC-9121515E65EF Q26859144-27285A9F-4D67-4508-92FD-F76DFD528ADF Q26859221-ABA717A1-0834-474C-A447-ACF8E9E4C4B7 Q27003261-B9A05EF8-3E09-467B-87A6-1759ED7D51CB Q27022557-E42B8321-70E5-4476-B5D0-1796A8CE8B79 Q27025558-DD9ED27D-5CE0-4345-BAC5-EAF16C76CD99 Q27345200-56A47DD8-3A9E-45C8-AB92-8C48F18CD053 Q28068930-62869458-EED6-48D7-993D-7A37005EBB71 Q28073025-6A6F036E-B687-4BF5-B2F0-C57F0EC94956 Q28079766-B8DA5D89-197E-4698-9B0A-C8882F3AF99A Q28080727-682605C7-9562-41AC-A5CF-53DF7FD87F8A Q28081200-0D6A6AF1-C4F3-42D0-B378-3C8453487AA1 Q28082687-0D6C8864-9E7E-485F-933C-AA04B9F8DE94 Q28082746-AD5D9367-141D-4CBC-97C8-BCF41FDCBB0D Q28083100-0ABA000A-A92D-47F0-BB96-670B7503227E Q28083449-3840FF76-6E10-456B-8C90-238DB7BA68A9 Q28083875-73100D0F-8068-4FB2-B186-3681CB98A4DA Q28115755-3B65403E-15B2-4C35-9378-B8EF7714CEB5 Q28537969-F5C5F5D1-CAE8-4FB9-A0FE-67CB7FA37F96 Q28541963-046EBBC2-ED2D-4BBF-9294-726821C154E6 Q28544873-EE96AC61-D7C0-4050-9D70-70E3FC6EE827 Q28551326-22FA54EE-8331-42F6-AC15-3F6BC490353F Q28607687-8BB138A2-07BD-4BC5-8B49-1F198D7ABF83 Q28612763-F4503DD9-51B8-4E7F-A945-43A84F4CD601 Q31134780-E7984D95-E96B-4AE9-B3BE-4D9163E61EB1 Q33576773-2EA5DAC5-6A06-4969-9FA7-9FCAE81C6ABE Q33603164-ABF4CB09-ECB9-4D68-81E1-DB2D6A354EE1 Q33632120-04EE44CF-0656-4C7B-80F0-1AE29903A2ED Q33633288-E2C0D047-FE10-4173-A510-8A76FDFA30B8 Q33633953-81E84261-72A2-429C-828A-7B0C294CAE3A Q33637143-0D73965E-0B7F-4DF0-99D2-4521231EE75D Q33905391-F0E68893-F83D-47C2-B4A5-2688A817C357

P2860

Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing

http://www.wikidata.org/entity/Q24632749

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Clinical Pharmacogenetics Impl ...... genotype and thiopurine dosing

@ast

Clinical Pharmacogenetics Impl ...... genotype and thiopurine dosing

@en

Clinical Pharmacogenetics Impl ...... genotype and thiopurine dosing

@nl

type

label

Clinical Pharmacogenetics Impl ...... genotype and thiopurine dosing

@ast

Clinical Pharmacogenetics Impl ...... genotype and thiopurine dosing

@en

Clinical Pharmacogenetics Impl ...... genotype and thiopurine dosing

@nl

prefLabel

Clinical Pharmacogenetics Impl ...... genotype and thiopurine dosing

@ast

Clinical Pharmacogenetics Impl ...... genotype and thiopurine dosing

@en

Clinical Pharmacogenetics Impl ...... genotype and thiopurine dosing

@nl

P1433

Q24632749-6847D26A-CBD4-4B89-9435-5939F5B33C13

P1476

Q24632749-051FC79D-36EA-4C5C-8825-2531319790B9

P2093

Q24632749-056F60D3-EF7B-4930-A2CA-3630D8FBC9F7

Q24632749-1BE5C566-C992-4641-BBC6-ECD276899D8C

Q24632749-5090DD72-4DD9-4418-8FEE-AE45D147EE41

Q24632749-7933431E-6F0C-40BC-B6D2-C487D6D368F1

Q24632749-85A99E92-7FE6-48DA-81AF-8177A4A9B230

Q24632749-A70AC307-5755-41A8-B7C3-82B36FFA472F

Q24632749-A9A20C64-F742-4088-82E9-1ECF92739366

Q24632749-B51C48E8-1040-415F-9A26-8FC9C4368C8F

Q24632749-E49BD0A5-8180-4C9E-9B79-2E64043ED222

P2860

Q24632749-010F3BE1-DBF4-48B4-9828-9211530ABA7C

Q24632749-17B2BF6D-1ACF-423F-A277-F34495000C81

Q24632749-18029794-F10F-4CF0-9AE3-626C31BE0CCA

Q24632749-1DDAFDA7-79E7-4B14-AEC0-B41F1209C04A

Q24632749-23B27835-C0B9-424B-8200-F80ECE6942B2

Q24632749-25EAD0FF-20B4-4684-87F4-E69EA4D7F750

Q24632749-3B122CAC-81A7-438B-9385-CE56598A8DB0

Q24632749-40E7444E-1354-486B-95BE-47B2C30E6884

Q24632749-4461405B-983D-4F48-BC6F-E5A72E72B969

Q24632749-47D6FBD0-BACD-4155-9DC3-A1FDF4A62147

P304

Q24632749-F17ED198-F022-4814-95CE-F83A3A4C159D

P31

Q24632749-731E4969-BC59-4F0B-96C5-83208F53464E

P3181

Q24632749-6582498B-2CD7-434E-84A8-3455D79777B5

P356

Q24632749-A80C84CF-CD7B-4529-B508-BB38800C677D

P407

Q24632749-53714837-FFB4-40CA-B82D-40F6E3AEB18F

P433

Q24632749-5B71B328-DA84-4409-8DAC-04626B457041

P478

Q24632749-5393A1A7-0005-453C-8616-BC08385EA4A9

P50

Q24632749-397EBAC8-7F71-480E-A5B8-99915EE1FD81

P577

Q24632749-E1CF0306-0F30-431C-8AA6-4B600A488DED

P5875

Q24632749-5750D008-3D93-472E-8C50-9035F176079A

P698

Q24632749-5346AFC7-61E5-4C16-B716-98821DBA4619

P932

Q24632749-7A119B3E-2EF4-46F9-9B95-1CC7511F53E8

P3181

P356

P1433

Clinical Pharmacology & Therapeutics

P1476

Clinical Pharmacogenetics Impl ...... genotype and thiopurine dosing

@en

P2093

C M Stein

http://www.w3.org/2001/XMLSchema#string

C-H Pui

http://www.w3.org/2001/XMLSchema#string

E E Gardner

http://www.w3.org/2001/XMLSchema#string

M Carrillo

http://www.w3.org/2001/XMLSchema#string

M V Relling

http://www.w3.org/2001/XMLSchema#string

S W Yee

http://www.w3.org/2001/XMLSchema#string

T E Klein

http://www.w3.org/2001/XMLSchema#string

W E Evans

http://www.w3.org/2001/XMLSchema#string

W J Sandborn

http://www.w3.org/2001/XMLSchema#string

P2860

CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network

Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy

Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance

Rational dosing of azathioprine and 6-mercaptopurine

Severe 6-thioguanine-induced marrow aplasia in a child with acute lymphoblastic leukemia and inherited thiopurine methyltransferase deficiency.

Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine.

Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.

Inheritance and drug response.

Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain

Pharmacogenetics of cancer therapy: getting personal

P304

387-91

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3140921

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/CLPT.2010.320

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

89

http://www.w3.org/2001/XMLSchema#string

P50

Kjeld Schmiegelow

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49788773

http://www.w3.org/2001/XMLSchema#string

P698

21270794

http://www.w3.org/2001/XMLSchema#string

P932

3098761

http://www.w3.org/2001/XMLSchema#string